Madhubanti Mullick

The paper identifies GIV as a macrophage checkpoint suppressing reverse cholesterol transport and shows its inhibition restores cholesterol efflux, reducing plaque burden and systemic lipid overload.

This paper identifies two stromal states in IBD that predict clinical outcomes and shows that targeting one state can reverse disease pathology.

This paper identifies GIV as a macrophage-intrinsic factor that controls PD1 endocytosis, determining durable response versus hyperprogressive disease to PD1 blockade.

This paper identifies a host-encoded toggle switch involving NOD2 and GIV that controls cAMP levels in macrophages, converting tolerant cells into microbicidal machines to restore microbial clearance and gut barrier integrity.

The paper identifies niColAMs as critical for IBD recovery and shows GIV-NOD2 interaction is essential for microbial sensing and gut homeostasis.

F.O.R.W.A.R.D is a network-based target prioritization framework that uses clinical outcomes and transcriptomic data to predict drug efficacy in IBD, achieving 100% predictive accuracy in benchmarking.